Is Vascular Biogenics (VBLT) a good buy?

QuestionsIs Vascular Biogenics (VBLT) a good buy?
Stephen asked 2 months ago

Hi Lance. What are your thoughts on Vascular Biogenics (VBLT)?

1 Answers
Lance Jepsen answered 2 months ago

Good “story”/catalyst stock. VB-111 looks like it might pass FDA approval. Nanocarrier Co Ltd has already signed an exclusive agreement for VB-111 in Japan.

Also VBLT opened its new gene therapy manufacturing plant in Modiin, Israel which they claim is one of the largest gene-therapy plants in the world at 20,000 sq. ft. The company will use the plant to manufacture, in large-scale, VB-111. That's a lot of confidence other companies and the company itself is putting in VB-111 getting FDA approval.

The problem is that VBLT stock has already started to run higher ahead of their presentation on November 18, 2017 at SNO.

Chasing a biotech stock can be brutal and if you aren't willing to have dead-money socked away in such a stock for 6 months or more, than you probably shouldn't buy the stock. I prefer to wait for a consolidation instead of chasing it higher.

Leave a Reply

Your Answer